

CURRICULUM VITAE

Personal Details

Birthdate and gender	21/10/1963, male
First and last name	Thierry HUET
Country	France
Contact details	Mail: thierry.huet@vivadju.com – Mob.: +33 6 07 77 03 07

Current Position

CHIEF EXECUTIVE OFFICER (CEO)

Organization/Company

RNSR code	Company	Unit	Unit code	Zip code	City
	VIVADJU			75010	Paris

Skills & Competencies

Seasoned executive in R&D with more than 35 years of experience in the development of therapeutic products in biotechnology and pharmaceutical industries.

◆ MANAGEMENT

- Management of R&D divisions/departments/teams (up to 32 collaborators)
- Portfolio and Project Management of R&D programs within multidisciplinary (preclinic, clinic, manufacturing, regulatory affairs, marketing, ...) and multicultural (France – USA) teams from Research to Phase II clinical development
- Management of collaborations, partnerships (including coordination of due-diligence missions) and Contract Research Organizations (preclinic, clinic, toxicology, ADME, manufacturing, analytics, ...)
- Coordination of Regulatory Affairs activities
- Management of Phase I/II clinical trials
- Responsibilities in Business Development, strategy, finance, intellectual property, Human Resources and Corporate activities
- Reporting responsibilities at the Top Management level (CEO, Management Committee) and to the Board of Directors

◆ SCIENTIFIC AND TECHNICAL EXPERTISE

- Oncology/hematology, immunology, virology (AIDS) and cardiovascular/thrombosis
- Gene and cell therapies, monoclonal antibodies, therapeutic proteins and chemical entities
- Set up and follow up of R&D programs
- Project Management
- Preclinical and clinical development
- Manufacturing and analytics (viral and non-viral vectors, proteins and chemical entities)
- Development of bioassays for pharmacokinetics and diagnosis
- Regulatory documents (IMPD, IND, IB, ...), reports, publications, presentations and communications

Professional Experience

Start	End	Location	Organization/Company	Title/Function
September 2023 – Present			VIVADJU – Paris, France	CEO - Development of cell-mediated and/or humoral immunotherapy drugs – Nucleic acid-based vaccines – Hematologic and solid cancers
January 2024 – Present			HRDS CONSULTING – Nogent sur Marne, France	PRESIDENT & CONSULTANT Consulting and operational services for biopharmaceutical companies in terms of strategy, management, organization and development of R&D scientific and technical innovations

- September 2021 – July 2023** **DIRECTOR OF RESEARCH & DEVELOPMENT**
GENOMIC VISION – Bagneux, France
- Structural and functional analysis of genome modifications - Inherited genetic disorders - Age-related diseases – Cancer - Biomanufacturing - Quality Control
- October 2012 – August 2021** **DIRECTOR OF RESEARCH & DEVELOPMENT**
INVECTYS – Paris, France
- Development of cell-mediated and/or humoral immunotherapy drugs – Vaccines – Gene and cell therapies - Monoclonal antibodies – Cancer and infectious diseases
- October 2017 – August 2021** **BOARD MEMBER**
MEDICEN – Paris, France
Health competitiveness cluster of the Paris Region. Definition of the strategic directions, domains and objectives of the cluster, particularly within the SME-SMI college.
- July 2011 – October 2011** **CONSULTANT IN RESEARCH & DEVELOPMENT**
INNAVIRVAX – Paris, France: IMPD dossier, Investigator's Brochure, Clinical protocol – Therapeutic vaccine for treatment of AIDS
- November 2005 – June 2011** **DIRECTOR OF DEVELOPMENT & PROJECT MANAGEMENT**
ENDOTIS PHARMA – Romainville, France
- Development of oligosaccharide-based drugs in Thrombosis and Cancer - Life cycle management of marketed drugs through an oligosaccharide-based technology platform
- October 2004 – April 2005** **CONSULTANT IN RESEARCH & DEVELOPMENT**
PHARMALEADS – Paris, France: Development strategies – Diagnosis and Analgesia
DIATOS – Paris, France: IMPD dossier, Investigator's Brochure, Study Reports - Cancer
- July 2002 – May 2004** **DIRECTOR OF RESEARCH & DEVELOPMENT**
ABTECH PHARMA – Paris, France
- Development of therapeutic antibodies – Vascular and tumor targeting – Angiogenesis and anti-angiogenesis – Cancer and cardiovascular
- May 2001 – January 2002** **DIRECTOR OF RESEARCH & DEVELOPMENT**
DIATOS – Paris, France
- Intracellular drug delivery (chemical entities, peptides, proteins, antibodies and DNA) and tumor targeting – Cancer et infectious diseases
- June 1991 – April 2001** **R&D TEAM AND PRECLINICAL STUDY MANAGER**
SANOFI – AVENTIS - RHÔNE-POULENC RORER
Research Center of Vitry-Alfortville, France and Hayward, California, USA
- 1996 - 2001: Gencell – Cancer gene therapy
- 1995: Gencell - AIDS gene therapy
- 1992 - 1994: Anti-AIDS pharmacology
- 1991: Cardiovascular/atherosclerosis program
- January 1991 – May 1991** **RESEARCH TEAM MANAGER**
HUMAN POLYMORPHISM STUDY CENTER, Paris, France
Retrovirology Department
- Gene therapy for degenerative muscular diseases
- January 1987 – December 1990** **PH.D. THESIS**
PASTEUR INSTITUTE, Paris, France
Molecular Biology and Immunology of Retroviruses Department
- Genetic and functional diversity of AIDS viruses

April 1985 – December 1986 **MASTER'S STUDENT**
CANCER RESEARCH INSTITUTE, Villejuif, France
Molecular Oncology Department
- Genetic evolution of the *p53* gene

Education

January 2013 **Executive Certificate** in General Management and Strategy - ESCP Business School (Paris)

October 1990 **Ph.D. (Doctorat ès Science)** in Microbiology, Virology
Pierre and Marie Curie University (Paris VI)

September 1986 **Master's Degree (DEA)** in Microbiology, Virology - University of Paris VI

1983 - 1985 First and Second Cycles in Biology, University of Paris VI

Scientific Publications

- 20 publications in international journals (list available on request)
- More than 70 oral communications or posters at international conferences

5 major publications

Major contribution of the publication

1	<p>GERMAIN C, GARIBAL J, DOPPLER V, BARAN-MARSZAC F, CYMBALISTA F, CAUMARTIN J, LANGLADE-DEMOYEN P, WEHBE M AND HUET T.</p> <p>Anti-telomerase immune response predicts disease progression in chronic lymphocytic leukemia.</p> <p><i>Clinical Immunology Communications</i> 1, :35-44, 2021.</p>	<p>The anti-telomerase immune response is a prognosis marker of the progression of the chronic lymphocytic leukemia (CLL)</p>
2	<p>TEIXEIRA L, MEDIONI J, GARIBAL J, ADOTEVI O, DOUCET L, DRAGON DUREY MA, GHRIEB Z, KILADJIAN JJ, BRIZARD M, LAHEURTE C, WEHBE M, PLIQUET E, ESCANDE M, DEFRANCE R, CULINE S, OUDARD S, WAIN-HOBSON S, DOPPLER V, HUET T AND LANGLADE DEMOYEN P.</p> <p>A first-in-human phase I study of INVAC-1, an optimized human telomerase DNA vaccine in patients with advanced solid tumors.</p> <p><i>Clin. Cancer Res.</i> 26(3): 588-597, 2020. PMID: 31558479</p>	<p>Clinical and immunological results of a Phase I in patients with solid cancers evaluating a DNA vaccine (INVAC-1). No toxicity, strong T cell immune responses, 50% clinical responses (PR and SD)</p>
3	<p>THALMENSI J, PLIQUET E, LIARD C, ESCANDE M, BESTETTI, JULITHE M, KOSTRZAK A, PAILHES-JIMENEZ AS, BOURGES E, LOUSTAU M, CAUMARTIN J, LACHGAR A, HUET T, WAIN-HOBSON S & LANGLADE-DEMOYEN P.</p> <p>Anti-cancer DNA vaccine based on human telomerase reverse transcriptase generates a strong and specific T-cell immune response.</p> <p><i>Oncoimmunology</i> 5(3):e1083670, 2016. PMID: 27141336</p>	<p>POC of the pharmacological effectiveness of a DNA vaccine (INVAC-1) in animal tumor models. Strong T cell immune responses and reliable anti-tumor effects</p>
4	<p>HUET T, KERBARH O, SCHOLS D, CLAYETTE P, GAUCHET C, DUBREUCQ G, VINCENT L, BOMPAIS H, MAZINGHIEN R, QUEROLLE O, SALVADOR A, LEMOINE J, LUCIDI B, BALZARINI J.& PETITOU M.</p> <p>Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-Human Immunodeficiency Virus type 1 activity.</p>	<p>POC of the pharmacological effectiveness of a long-lasting anti-fusion derivative (LL-enfuvirtide) against HIV infection. This derivative was more potent than the original drug (enfuvirtide)</p>

	Antimicrob. Agents Chemother. 54: 134-142, 2010. PMID: 19805567	
5	BOUGERET C, VIRONE-ODDOS A. ADELINE E, LACROIX F, LEFRANC C, FERRERO L & HUET T. Cancer gene therapy mediated by CTS1, a p53 derivative: advantage over wild-type p53 in growth inhibition of human tumors overexpressing MDM2. Cancer Gene Ther. 7: 789-798, 2000. PMID: 10830726	POC of the pharmacological effectiveness of an improved p53 gene therapy product. This novel derivative, CTS-1, was more potent than the original molecule (p53)

Valorization

- 6 patents : Institut Pasteur, Endotis Pharma et Invectys (4) :

Langlade Demoyen P., **Huet T.**, Caumartin J., Loustau M., Wehbe M. *Anti-HLA-G specific antibodies*. Invectys. WO 2017/207775. Priority date: June 3, 2016.

Langlade Demoyen P., **Huet T.**, Wain-Hobson S., Kostrzak A. *Polyepitope constructs for use in immunotherapy*. Invectys. WO 2017/060360. Priority date: October 6, 2015.

Langlade Demoyen P., Wain-Hobson S., **Huet T.**, Liard C., Pliquet E. *A telomerase encoding DNA vaccine*. Invectys. WO 2015/063117. Priority date: October 28, 2013.

Langlade Demoyen P., **Huet T.**, Liard C., Thalmensi J., Mir L., Calvet C. *Gene electrotransfer into skin cells*. Invectys and CNRS. WO 2015/063112. Priority date: October 28, 2013.

Gauchet C., **Huet T.**, Lucidi B., Petitou M., Querolle O. *Oligosaccharide Derivatives*. Endotis Pharma. WO 2008/029278. Priority date: August 3, 2006.

Wain-Hobson S., **Huet T.**, Delaporte E., Brun-Vezinet F. *Isolation, molecular cloning and sequencing of an HIV-1 isolate from a Gabonese donor*. Pasteur Institute. US 5,019,510 (1991). Priority date: October 28, 1987.